|
1
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
Blood
|
2002
|
4.00
|
|
2
|
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
|
Blood
|
2002
|
3.60
|
|
3
|
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
|
N Engl J Med
|
1994
|
3.26
|
|
4
|
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
|
Blood
|
2002
|
2.33
|
|
5
|
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2004
|
2.32
|
|
6
|
Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe.
|
Emerg Infect Dis
|
2003
|
2.12
|
|
7
|
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
|
Blood
|
2005
|
2.06
|
|
8
|
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
|
Blood
|
2003
|
2.00
|
|
9
|
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
|
J Clin Oncol
|
2007
|
1.94
|
|
10
|
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.
|
Blood
|
2002
|
1.92
|
|
11
|
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
|
Haematologica
|
2002
|
1.91
|
|
12
|
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
|
Haematologica
|
2005
|
1.82
|
|
13
|
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.
|
Haematologica
|
2008
|
1.54
|
|
14
|
Consensus conference on the management of tumor lysis syndrome.
|
Haematologica
|
2008
|
1.49
|
|
15
|
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
Haematologica
|
2002
|
1.47
|
|
16
|
Primary bone lymphoma: experience with 52 patients.
|
Haematologica
|
2003
|
1.43
|
|
17
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
|
18
|
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2011
|
1.25
|
|
19
|
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2008
|
1.20
|
|
20
|
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
|
Blood
|
2002
|
1.15
|
|
21
|
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells.
|
Blood
|
2004
|
1.11
|
|
22
|
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.
|
Haematologica
|
2009
|
1.11
|
|
23
|
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
|
Hematology Am Soc Hematol Educ Program
|
2000
|
1.10
|
|
24
|
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
|
J Clin Oncol
|
2003
|
1.09
|
|
25
|
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
|
Eur J Haematol
|
2006
|
0.99
|
|
26
|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
|
Blood
|
2006
|
0.98
|
|
27
|
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
|
Blood
|
2002
|
0.97
|
|
28
|
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
|
J Clin Oncol
|
2004
|
0.97
|
|
29
|
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.
|
Blood
|
2002
|
0.92
|
|
30
|
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.
|
Haematologica
|
2003
|
0.92
|
|
31
|
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
|
Eur J Haematol
|
2005
|
0.91
|
|
32
|
Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
|
Blood
|
2002
|
0.91
|
|
33
|
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.
|
Haematologica
|
2013
|
0.91
|
|
34
|
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2006
|
0.90
|
|
35
|
Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients.
|
Leuk Lymphoma
|
2003
|
0.89
|
|
36
|
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.
|
Exp Hematol
|
2006
|
0.89
|
|
37
|
Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2005
|
0.88
|
|
38
|
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
|
Ann Hematol
|
2012
|
0.87
|
|
39
|
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2008
|
0.87
|
|
40
|
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
|
Haematologica
|
2002
|
0.87
|
|
41
|
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).
|
Haematologica
|
2004
|
0.86
|
|
42
|
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
|
Haematologica
|
2006
|
0.85
|
|
43
|
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
|
Eur J Haematol
|
2004
|
0.85
|
|
44
|
Stem cell plasticity: time for a reappraisal?
|
Haematologica
|
2005
|
0.82
|
|
45
|
Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade.
|
Exp Hematol
|
2003
|
0.82
|
|
46
|
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
|
Haematologica
|
2002
|
0.82
|
|
47
|
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
|
Eur J Haematol
|
2014
|
0.81
|
|
48
|
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.
|
Am J Hematol
|
2013
|
0.80
|
|
49
|
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
|
Haematologica
|
2002
|
0.79
|
|
50
|
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2004
|
0.78
|
|
51
|
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
52
|
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2004
|
0.77
|
|
53
|
Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant.
|
Exp Hematol
|
2003
|
0.77
|
|
54
|
Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.
|
Exp Hematol
|
2002
|
0.76
|
|
55
|
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
|
Haematologica
|
2003
|
0.75
|
|
56
|
Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1).
|
Haematologica
|
2002
|
0.75
|
|
57
|
Pulmonary disease in patients with hematologic malignancies.
|
Sarcoidosis Vasc Diffuse Lung Dis
|
2002
|
0.75
|
|
58
|
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.
|
Eur J Haematol
|
2007
|
0.75
|
|
59
|
Efficacy of thalidomide in the treatment of myelodysplastic syndromes.
|
Haematologica
|
2002
|
0.75
|
|
60
|
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
|
Am J Hematol
|
2010
|
0.75
|
|
61
|
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study.
|
Ann Hematol
|
2011
|
0.75
|
|
62
|
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.
|
Leuk Res
|
2011
|
0.75
|
|
63
|
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
|
Leuk Lymphoma
|
2004
|
0.75
|
|
64
|
Immune therapy of chronic myelogenous leukemia.
|
Leuk Res
|
2005
|
0.75
|
|
65
|
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
66
|
High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience.
|
Haematologica
|
2003
|
0.75
|